The Evolving Landscape of Minimally Invasive BPH Therapy

Welcome to this Urology Times Insights series, "Less Invasive BPH Therapy: Real-World Results." In this episode, Rahul Mehan, MD, founder and CEO of East Valley Urology Center in Arizona, sets the stage for the series.

Mehan opens the series by outlining 3 forces reshaping benign prostatic hyperplasia (BPH) care. Patients' expectations have changed, he explains. They want to know not just how much their symptoms will improve, but how quickly they can return to work, whether they'll need a catheter, and whether the procedure will affect erections or ejaculation. He also points to a widening gap between medication and traditional surgery that minimally invasive therapies now fill, along with rapid technological gains across mechanical, thermal, and drug-coated approaches that let urologists individualize treatment to a patient's anatomy, symptom severity, and goals.

Mehan then walks through how he actually chooses among those options. Treatment selection, he stresses, is a shared medical decision built on a first-visit transrectal ultrasound. He looks closely at prostate size and shape: lateral lobe obstruction vs a significant median lobe, bladder neck position, and prostatic urethral length, because those details determine which minimally invasive therapy is likely to succeed. Mechanical therapies tend to suit smaller, favorable-anatomy glands where preserving ejaculation is a priority; thermal therapies work across a broader anatomic range but come with a slower, more gradual recovery; and ablative approaches fit patients with larger glands, higher residuals, or a desire for a more definitive result. He also weighs bladder function, anticoagulation, anesthesia risk, and how badly a patient wants to avoid the operating room.

Mehan closes this segment by explaining what's driving patients away from indefinite medical therapy in the first place: modest symptom relief from alpha-blockers, bothersome adverse events, and a more informed patient population that increasingly wants to address the underlying mechanical problem rather than manage it daily.

In the next episode, Mehan shares his real-world experience with drug-coated balloon dilation for BPH, comparing his own outcomes with the PINNACLE trial and walking through the learning curve, recovery, and safety counseling that come with adopting it in practice.